Baseline, repeated-measure burden, and two-time-point patterns of the triglyceride-glucose index-visceral lipid ratio (TyG-VLR) and incident cardiovascular disease in cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3: a longitudinal China Health and Retirement Longitudinal Study (CHARLS) analysis [0.03%]
中国健康与退休纵向研究(CHARLS)中心血管-肾脏-代谢(CKM)综合征0-3期的甘油三酯-葡萄糖指数-腹脂比率(TyG-VLR)基线、重复测量负担和双时点模式以及随后发生的心血管疾病：纵向分析
Ao-Men Lu,Hao-Jie Han,Qian Xu et al.
Ao-Men Lu et al.
Background: Cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 define a population without overt clinical cardiovascular disease (CVD) but with accumulating metabolic, adiposity, lipid, and kidney-related risk. We ...
A three-metabolite microbiota-associated signature for early risk stratification of gestational diabetes mellitus [0.03%]
三代谢物微生物组标志物用于妊娠期糖尿病早期风险分层
Shuo Ma,Chen Zhang,Yuming Yao et al.
Shuo Ma et al.
Background: Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes and long-term metabolic and cardiovascular risk. However, oral glucose tolerance testing at 24-28 gestational weeks limits earl...
Multicenter Study
Cardiovascular diabetology. 2026 Aug 7;25(1):214. DOI:10.1186/s12933-026-03278-x 2026
Association of the triglyceride-glucose index with subclinical left ventricular dysfunction in type 2 diabetes mellitus: mediation by myocardial energetic efficiency and resting perfusion [0.03%]
甘油三酯-葡萄糖指数与2型糖尿病左心室功能不全的关联：心肌能量效率和静息灌注的中介作用
Li Jiang,Yuan Li,Hua-Yan Xu et al.
Li Jiang et al.
Background: The triglyceride-glucose(TyG) index, a surrogate marker of insulin resistance, has been linked to cardiac dysfunction; however, its underlying associated pathways in patients with type 2 diabetes mellitus(T2DM...
STIM1-mediated Treg instability in HFpEF: a new immunological target emerges? [0.03%]
HFpEF中STIM1介导的Treg不稳定：新的免疫学靶点出现？
Anna Planavila,Albert Blasco-Roset
Anna Planavila
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and remains a major unmet clinical challenge. Increasing evidence supports the view of HFpEF as a systemic inflammatory syndrome driv...
Effect of empagliflozin on copeptin levels in patients with recent acute coronary syndrome and newly detected dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial [0.03%]
恩格列净对近期急性冠脉综合征并新发糖代谢异常患者copeptin水平影响的探索：SOCOGAMI随机对照试验的事后分析
Elena Fortin,Olle Melander,Giulia Ferrannini et al.
Elena Fortin et al.
Background: Copeptin, a surrogate marker for vasopressin secretion, is associated with cardiovascular disease, insulin resistance and dysglycaemia. The cardioprotective effects of sodium-glucose cotransporter 2 inhibitors...
Randomized Controlled Trial
Cardiovascular diabetology. 2026 Jul 28;25(1):212. DOI:10.1186/s12933-026-03312-y 2026
Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage [0.03%]
达格列净和恩格列净的治疗可降低与血管损伤相关的血浆生物标志物N4-乙酰胞苷浓度
Arne Gessner,Dennis Kannenkeril,Agnes Bosch et al.
Arne Gessner et al.
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) provide cardiovascular and renal protection in both diabetic and non-diabetic patients at least in part independently of glycaemic control. Some underly...
Randomized Controlled Trial
Cardiovascular diabetology. 2026 Jul 24;25(1):210. DOI:10.1186/s12933-026-03292-z 2026
Association between body mass index reduction and epicardial adipose tissue changes across pharmacological and lifestyle interventions: a multilevel meta-regression analysis [0.03%]
体重指数降低与心脏外膜脂肪组织变化的关联：多水平元回归分析结果
Aleksandra Mączyńska,Piotr Olbryś,Mateusz Smoliński et al.
Aleksandra Mączyńska et al.
Background: Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot implicated in cardiometabolic disease. Although EAT reductions are commonly attributed to weight loss, the extent to which EAT chang...
Associations of cumulative exposure and dynamic trajectories of the cholesterol-HDL-glucose index and its obesity-related derivatives with cardiovascular disease: a nationwide prospective cohort study [0.03%]
胆固醇-高密度脂蛋白-血糖指数及其与肥胖相关衍生指标的累计暴露和动态轨迹与心血管疾病的关系：全国前瞻性队列研究
Han Wang,Guirong Song,Guorong Li et al.
Han Wang et al.
Background: Integrating metabolic biomarkers with anthropometric indicators has been shown to enhance the discriminative capacity for cardiovascular disease (CVD). However, the impact of the cholesterol-HDL-glucose index ...
Lipoprotein(a), insulin resistance, and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease [0.03%]
与代谢功能障碍相关肝脂肪变性疾病的载脂蛋白(a)、胰岛素抵抗和心血管预后
Bingtian Dong,Yuping Chen,Fang He et al.
Bingtian Dong et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with increased cardiovascular disease (CVD) risk. Lipoprotein(a) [Lp(a)] and insulin resistance (IR) are established cardiovascula...
Association between the combined cholesterol, high-density lipoprotein, glucose index and frailty index and new-onset cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: evidence from CHARLS [0.03%]
胆固醇、高密度脂蛋白、血糖指数与心血管代谢肾病综合征0～3期人群衰弱指数关联及新发心血管疾病效应研究：来自CHARLS的证据
Zhonghua Sun,Kexue Wang,Chiwei Guo et al.
Zhonghua Sun et al.
Background: Early-stage cardiovascular-kidney-metabolic (CKM) syndrome, encompassing stages 0-3, represents a critical window for identifying individuals at risk before the development of clinical cardiovascular disease (...